News | November 09, 2009

PAREXEL Enhances Early-Phase Cardiac Safety Capabilities Through Alliance With Mortara Instrument

November 9, 2009 — PAREXEL International Corp., a global biopharmaceutical services provider, announced today that it has enhanced its cardiac safety capabilities for early-phase clinical development through an alliance with Mortara Instrument Inc., which manufactures and distributes electrocardiogram (ECG) devices and related technology worldwide.

PAREXEL is using Mortara Instrument's Surveyor Telemetry Central System to supplement its state-of-the-art ECG equipment to support biopharmaceutical companies in improving cardiac safety assessment of new compounds.

Designed to address the growing ECG requirements of early-phase cardiac safety studies, Mortara's Surveyor Telemetry Central System allows PAREXEL to acquire and store continuous, diagnostic 12-lead ECG data, which is wirelessly transmitted from devices worn by clinical trial participants.

The Mortara solution, which has been fully implemented and validated in PAREXEL's early-phase clinical unit located in Baltimore, provides live monitoring and automated acquisition and recording of ECGs for analysis and transmission to core labs. This solution extends the technology capabilities for ECG and QT/QTc studies conducted in PAREXEL's other early-phase units worldwide, including sites located in Los Angeles, London, Berlin, and Bloemfontein, George, and Port Elizabeth, South Africa.

Each of PAREXEL's early-phase clinical units has state-of-the-art equipment and performs cardiac studies according to international guidelines. The units are equipped with telemetric and bedside monitoring as well as ECG equipment for continuous registration. PAREXEL's early phase experts provide top-quality, evidence-supported readings of clinical cardiovascular data and work in collaboration with ECG core labs. PAREXEL's early phase services include a wide range of cardiovascular-related capabilities, including study design, project monitoring, data management, and biostatistics.

PAREXEL's early-phase services provide fully integrated solutions from first in man through proof of concept and help biopharmaceutical companies generate better and faster go/no-go decisions about their compounds, and strive to return solid, reproducible outcomes to succeed in later-phase trials. PAREXEL's early phase capabilities include a full scope of early phase studies, specialized trial design, state-of-the-art technologies, hospital-based resources, and scientific expertise as well as vast experience in the neurology, cardiology, respiratory, and metabolism/endocrine therapeutic areas. With early phase unit locations across three continents, PAREXEL provides rapid study start-up and access to diverse patient populations in addition to healthy volunteers.

For more information: www.parexel.com/Early_Phase.html, www.mortara.com

Related Content

ECG Study of NBA Players Shows Need for Sport-Specific Normative Data and Guidelines
News | ECG| December 08, 2017
Cardiologists at NewYork-Presbyterian/Columbia University Irving Medical Center compared electrocardiographic findings...
HeartSciences Announces CE Mark and European Launch of MyoVista High Sensitivity ECG

Just as a Doppler radar color image shows the energy of a storm, MyoVista provides physicians a detailed visual image of the energy distribution during the cardiac cycle.

News | ECG| August 22, 2017
HeartSciences announced the European launch of the MyoVista high sensitivity electrocardiograph (hsECG) Testing Device...
AUM Cardiovascular Receives FDA Approval for CADence ECG Device
Technology | ECG| August 08, 2017
AUM Cardiovascular announced it has received clearance from the U.S. Food and Drug Administration (FDA) for CADence, a...
More Than 20 Percent of Low-Risk Patients Receive Annual ECG
News | ECG| July 20, 2017
July 20, 2017 — More than one in five Ontario patients receive an ...
Heart Test Laboratories, HTL, MyoVista ECG, common stock offering
News | ECG| January 31, 2017
Heart Test Laboratories Inc. (HTL) has successfully raised $12 million by way of a Common Stock private placement...
AirStrip One, ECG management, web client, U.S. clearance
Technology | ECG| October 11, 2016
The U.S. Food and Drug Administration (FDA) has issued 510(K) Class II clearance to a web client for the AirStrip One...
Carestream, Vue Motion universal viewer, ECG waveforms, diagnostic reading, FDA clearance

Image courtesy of Carestream Health

Technology | ECG| November 20, 2015
Carestream has obtained U.S. Food and Drug Administration (FDA) clearance for diagnostic reading of electrocardiogram (...
CardioSecur mobile ECG, 22-lead, 360 degree view of the heart, CardioSecur Pro

Image courtesy of CardioSecur

Technology | ECG| October 08, 2015
Personal MedSystems introduced the first and only 22-lead mobile electrocardiogram (ECG) system, CardioSecur, at the...
Mortara, ELI 280, TouchScreen ECG, ECG advances, new ECG technology

The Mortara Eli 280 is part of a new generation of ECG systems that integrate touchscreen monitors to improve workflow.

Feature | ECG| September 16, 2015 | Dave Fornell
The resting electrocardiogram (ECG) has been us
zebrafish, iWorx Systems Inc., ZS-200 Zebrafish ECG System, cardiac research
Technology | ECG| August 13, 2015
iWorx Systems Inc., developer of advanced physiology teaching and research instruments and software, has introduced a...
Overlay Init